Top-Rated StocksTop-RatedNASDAQ:DFTX Definium Therapeutics (DFTX) Stock Price, News & Analysis $24.19 +0.71 (+3.02%) As of 05/29/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Definium Therapeutics Stock (NASDAQ:DFTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Definium Therapeutics alerts:Sign Up Key Stats Today's Range$23.30▼$24.2950-Day Range$17.50▼$24.1952-Week Range$6.34▼$26.25Volume2.31 million shsAverage Volume1.49 million shsMarket Capitalization$2.41 billionP/E RatioN/ADividend YieldN/APrice Target$37.92Consensus RatingBuy Company Overview Definium Therapeutics, Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York. AI Generated. May Contain Errors. Read More Definium Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks65th Percentile Overall ScoreDFTX MarketRank™: Definium Therapeutics scored higher than 65% of companies evaluated by MarketBeat, and ranked 438th out of 870 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingDefinium Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 12 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialDefinium Therapeutics has a consensus price target of $37.92, representing about 56.8% upside from its current price of $24.19.Amount of Analyst CoverageDefinium Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Definium Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Definium Therapeutics are expected to grow in the coming year, from ($2.26) to ($1.85) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Definium Therapeutics is -9.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Definium Therapeutics is -9.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDefinium Therapeutics has a P/B Ratio of 8.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.49% of the float of Definium Therapeutics has been sold short.Short Interest Ratio / Days to CoverDefinium Therapeutics has a short interest ratio ("days to cover") of 6.63.Change versus previous monthShort interest in Definium Therapeutics has recently decreased by 1.14%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDefinium Therapeutics does not currently pay a dividend.Dividend GrowthDefinium Therapeutics does not have a long track record of dividend growth. News and Social Media3.1 / 5News Sentiment0.93 News SentimentDefinium Therapeutics has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.83 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Definium Therapeutics this week, compared to 5 articles on an average week.Search InterestOnly 19 people have searched for DFTX on MarketBeat in the last 30 days. This is a decrease of -59% compared to the previous 30 days.MarketBeat Follows15 people have added Definium Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership0.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Definium Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders2.26% of the stock of Definium Therapeutics is held by insiders.Percentage Held by Institutions27.91% of the stock of Definium Therapeutics is held by institutions.Read more about Definium Therapeutics' insider trading history. Receive DFTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Definium Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DFTX Stock News HeadlinesDefinium Therapeutics, Inc. (NASDAQ:DFTX) Given Average Recommendation of "Buy" by BrokeragesMay 25, 2026 | americanbankingnews.comJefferies Reaffirms Their Buy Rating on Definium Therapeutics (DFTX)May 22, 2026 | theglobeandmail.comI paid $5,000 to hear Elon say thisOne investor paid $5,000 to be in a private room with Elon Musk in Los Angeles - and what he heard confirmed a conviction 15 years in the making. Musk is launching a project 27 years in the making that could be his biggest move yet. One analyst believes there is a single stock positioned to benefit most - and he is giving away the name for free.May 30 at 1:00 AM | InvestorPlace (Ad)Definium Therapeutics: High-Stakes Data Readouts Poised To Validate Best-In-Class PotentialMay 21, 2026 | seekingalpha.comDefinium Therapeutics to Participate in the 2026 Jefferies Global Healthcare ConferenceMay 21, 2026 | businesswire.comDefinium Begins Second Phase 3 DT120 Trial As Valuation Gap WidensMay 21, 2026 | finance.yahoo.comDefinium Therapeutics Nears Pivotal Earnings Call TestsMay 20, 2026 | tipranks.comDefinium Highlights Late-Stage Psychedelic-Inspired Psychiatric PipelineMay 19, 2026 | tipranks.comSee More Headlines DFTX Stock Analysis - Frequently Asked Questions How have DFTX shares performed this year? Definium Therapeutics' stock was trading at $13.39 at the start of the year. Since then, DFTX shares have increased by 80.7% and is now trading at $24.19. How were Definium Therapeutics' earnings last quarter? Definium Therapeutics, Inc. (NASDAQ:DFTX) issued its earnings results on Friday, May, 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by $0.23. Read the conference call transcript. When did Definium Therapeutics' stock split? Definium Therapeutics's stock reverse split on the morning of Monday, August 29th 2022.The 1-15 reverse split was announced on Monday, August 29th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Definium Therapeutics? Shares of DFTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/08/2026Today5/30/2026Jefferies Global Healthcare Conference 20266/03/2026AGM 20266/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (10m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 DFTX's financial health is in the Green zone, according to TradeSmith. DFTX has been in this zone for over 10 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryHealthcare Current SymbolNASDAQ:DFTX CIK1813814 Webdefiniumtx.com Phone212 220 6633FaxN/AEmployees40Year Founded2019Price Target and Rating Average Price Target for Definium Therapeutics$37.92 High Price Target$70.00 Low Price Target$20.00 Potential Upside/Downside+56.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)($2.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$183.79 million Net MarginsN/A Pretax MarginN/A Return on Equity-100.30% Return on Assets-69.22% Debt Debt-to-Equity Ratio0.15 Current Ratio4.69 Quick Ratio4.69 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.80 per share Price / Book8.64Miscellaneous Outstanding Shares99,700,000Free Float97,445,000Market Cap$2.41 billion OptionableOptionable Beta2.37 Social Links 10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (NASDAQ:DFTX) was last updated on 5/30/2026 by MarketBeat.com Staff. From Our PartnersLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredPresident Trump just sparked a stock market MELT UPThe real reason Musk, Huang, Cook, and Fink just flew to Beijing Last week, the CEOs of Nvidia, Apple, Spac...Stansberry Research | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredSkip the Line Opportunity: The SpaceX IPOFormer tech executive and angel investor Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before their h...Brownstone Research | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Definium Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Definium Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
